Undiagnosed Diseases Network

Last updated

The Undiagnosed Diseases Network (UDN) is a research study that is funded by the National Institutes of Health Common Fund. Its purpose is to bring together clinical and research experts from across the United States to solve the most challenging medical mysteries using advanced technologies. [1] [2] [3] [4] [5] [6]

Contents

UDN was established in 2014 [7] with seven clinical sites located at medical institutions across the United States. As of 2019, twelve clinical sites are open. Shared resources include a central biorepository, sequencing core, metabolomics core, and animal research centers. [8]

History

In 2008, the National Institute of Health (NIH) established the Undiagnosed Diseases Program (UDP), with the intent to provide medical care to patients with rare diseases seeking a diagnosis and to discover new pathways and mechanisms involved in disease. [9] At the time, ongoing genomic research and advances in DNA sequencing strengthened the potential for successes in precision medicine, providing a stimulus to the objectives of the UDP. [10] The UDP, initially founded within the NIH Intramural Research Program, has now evolved into the Undiagnosed Diseases Network (UDN) and is funded by the NIH Common Fund. Upon its launch, the UDN consisted of the UDP, six additional clinical sites around the nation, a coordinating center, two DNA sequencing cores, a model organisms screening center, a metabolomics core, and a central biorepository. In seven years, the UDP received 2954 complete applications and evaluated 863 individuals. [11]

In September 2015, the UDN opened an online portal for patient applications, signifying the official launch of the UDN. By December 2019, 4077 patients had been referred to the UDN, and around 40% of the cases were accepted. 374 patients have received a diagnosis. [12]

Institutes and locations

Clinical sites

At clinical sites, accepted UDN participants undergo comprehensive medical examinations, family history studies, physical examinations, collection of biological specimens, laboratory tests, consultations, and imaging studies. Evaluations are typically conducted over a five-day period, with follow-up visits scheduled if necessary. [13]

As of 2019, twelve clinical sites are open; the National Institutes of Health (Bethesda, MD), Harvard Medical School, Duke University in collaboration with Columbia University, Baylor College of Medicine, University of California at Los Angeles, University of Miami, Vanderbilt University School of Medicine, Stanford University, University of Pennsylvania, University of Utah, University of Washington, Washington University in St. Louis. [8]

Central Biorepository

The UDN Central Biorepository (UDNCB) receives roughly 1,200 biological samples each year from the combined clinical sites. Through the UDN online portal, clinical sites can view, submit, and request samples, as well as review contact information for the UDNCB. Biological samples prioritized by the UDNCB include DNA, serum, plasma, urine, and peripheral blood mononuclear cells (PBMCs). [13] The UDNCB is located at Vanderbilt University Medical Center in Nashville, Tennessee. [8]

Sequencing core

The UDN sequencing core, located at Baylor College of Medicine (Houston, TX), receives blood samples from the clinical sites and uses blood-derived DNA to conduct whole-genome sequencing (WGS) and whole-exome sequencing (WES) on patients and relevant family members. [13]

Metabolomics core

The UDN metabolomics core analyzes the biological samples collected in the UDN by performing untargeted metabolite profiling via analytical platforms such as GC-MS and NMR, targeted/quantitative metabolite profiling of key metabolites, and bioinformatics, and provides clinical interpretation to patients. [13] The metabolomics core is located at Mayo Clinic in Rochester, Minnesota.

Model Organism Screening Centers

The two Model Organism Screening Centers (MOSCs) of the UDN are located at Baylor College of Medicine (Houston, TX) and Washington University in St. Louis (St. Louis, MO). These centers conduct research using the model organisms D. melanogaster (fruit fly), C. elegans (nematode worm), andD. rerio (zebrafish). By examining the effects of certain rare functional variants in these model organisms, the MOSCs investigate the contribution of patients' genetic variants to the pathogenicity of their diseases. [14]

See also

Related Research Articles

<i>Mycoplasma genitalium</i> Species of bacterium

Mycoplasma genitalium is a sexually transmitted, small and pathogenic bacterium that lives on the mucous epithelial cells of the urinary and genital tracts in humans. Medical reports published in 2007 and 2015 state that Mgen is becoming increasingly common. Resistance to multiple antibiotics is becoming prevalent, including to azithromycin, which until recently was the most reliable treatment. The bacteria was first isolated from the urogenital tract of humans in 1981, and was eventually identified as a new species of Mycoplasma in 1983. It can cause negative health effects in men and women. It also increases the risk factor for HIV spread with higher occurrences in those previously treated with the azithromycin antibiotics.

<span class="mw-page-title-main">Personalized medicine</span> Medical model that tailors medical practices to the individual patient

Personalized medicine, also referred to as precision medicine, is a medical model that separates people into different groups—with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease. The terms personalized medicine, precision medicine, stratified medicine and P4 medicine are used interchangeably to describe this concept though some authors and organisations use these expressions separately to indicate particular nuances.

<span class="mw-page-title-main">Incidental medical findings</span>

Incidental medical findings are previously undiagnosed medical or psychiatric conditions that are discovered unintentionally and during evaluation for a medical or psychiatric condition. Such findings may occur in a variety of settings, including routine medical care, during biomedical research, during post-mortem autopsy, or during genetic testing.

<span class="mw-page-title-main">Medical microbiology</span> Branch of medical science

Medical microbiology, the large subset of microbiology that is applied to medicine, is a branch of medical science concerned with the prevention, diagnosis and treatment of infectious diseases. In addition, this field of science studies various clinical applications of microbes for the improvement of health. There are four kinds of microorganisms that cause infectious disease: bacteria, fungi, parasites and viruses, and one type of infectious protein called prion.

<span class="mw-page-title-main">Eva Feldman</span> American neurologist

Eva Lucille Feldman, M.D., Ph.D., F.A.A.N., F.A.N.A. is an American physician-scientist and one of the world’s leading authorities on neurodegenerative disease. Currently, she serves as the Russell N. DeJong Professor of Neurology at the University of Michigan, as well as Director of the NeuroNetwork for Emerging Therapies and ALS Center of Excellence at Michigan Medicine. She was also recently named the James W. Albers Distinguished University Professor of Neurology, the highest faculty honor at the university.

<span class="mw-page-title-main">Human Microbiome Project</span> Former research initiative

The Human Microbiome Project (HMP) was a United States National Institutes of Health (NIH) research initiative to improve understanding of the microbiota involved in human health and disease. Launched in 2007, the first phase (HMP1) focused on identifying and characterizing human microbiota. The second phase, known as the Integrative Human Microbiome Project (iHMP) launched in 2014 with the aim of generating resources to characterize the microbiome and elucidating the roles of microbes in health and disease states. The program received $170 million in funding by the NIH Common Fund from 2007 to 2016.

<span class="mw-page-title-main">William A. Gahl</span> American geneticist

William A. Gahl currently serves as the Clinical Director of the National Human Genome Research Institute at the NIH main campus in Bethesda, MD.

A biorepository is a facility that collects, catalogs, and stores samples of biological material for laboratory research. Biorepositories collect and manage specimens from animals, plants, and other living organisms. Biorepositories store many different types of specimens, including samples of blood, urine, tissue, cells, DNA, RNA, and proteins. If the samples are from people, they may be stored with medical information along with written consent to use the samples in laboratory studies.

<span class="mw-page-title-main">W. Ian Lipkin</span> Professor, microbiologist, epidemiologist

Walter Ian Lipkin is the John Snow Professor of Epidemiology at the Mailman School of Public Health at Columbia University and a professor of Neurology and Pathology at the College of Physicians and Surgeons at Columbia University. He is also director of the Center for Infection and Immunity, an academic laboratory for microbe hunting in acute and chronic diseases. Lipkin is internationally recognized for his work with West Nile virus, SARS and COVID-19.

Translational research is research aimed at translating (converting) results in basic research into results that directly benefit humans. The term is used in science and technology, especially in biology and medical science. As such, translational research forms a subset of applied research.

<span class="mw-page-title-main">McDonnell Genome Institute</span>

McDonnell Genome Institute at Washington University in St. Louis, Missouri, is one of three NIH funded large-scale sequencing centers in the United States. Affiliated with Washington University School of Medicine and the Alvin J. Siteman Cancer Center, the McDonnell Genome Institute is creating, testing and implementing new approaches to the study of genomics with the goal of understanding human health and disease, as well as evolution and the biology of other organisms.

The Genomic Medicine Institute at the Cleveland Clinic is an inter-disciplinary institute and department that focuses on patient care, patient-oriented research, and outreach and education in personalized healthcare guided by genetics and genomics. It is located in the Center for Genomics Research Building in the Cleveland Clinic, in Cleveland, Ohio, United States of America.

<span class="mw-page-title-main">Benaroya Research Institute</span>

Benaroya Research Institute (BRI) is a Seattle, Washington non-profit organization that conducts medical research on many diseases and immune disorders, including autoimmune disease. It is affiliated with Virginia Mason Health System, and is located on the campus of Virginia Mason Medical Center.

Translational bioinformatics (TBI) is a field that emerged in the 2010s to study health informatics, focused on the convergence of molecular bioinformatics, biostatistics, statistical genetics and clinical informatics. Its focus is on applying informatics methodology to the increasing amount of biomedical and genomic data to formulate knowledge and medical tools, which can be utilized by scientists, clinicians, and patients. Furthermore, it involves applying biomedical research to improve human health through the use of computer-based information system. TBI employs data mining and analyzing biomedical informatics in order to generate clinical knowledge for application. Clinical knowledge includes finding similarities in patient populations, interpreting biological information to suggest therapy treatments and predict health outcomes.

The Pediatric Trials Network (PTN) is a consortium of clinical research sites located around the United States that are cooperating in the design and conduct of clinical trials to improve health care for young patients. The network is sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

<span class="mw-page-title-main">Diana W. Bianchi</span> American medical geneticist and neonatologist

Diana W. Bianchi is the director of the U.S. National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development, a post often called “the nation’s pediatrician.” She is a medical geneticist and neonatologist noted for her research on fetal cell microchimerism and prenatal testing. Bianchi had previously been the Natalie V. Zucker Professor of Pediatrics, Obstetrics, and Gynecology at Tufts University School of Medicine and founder and executive director of the Mother Infant Research Institute at Tufts Medical Center. She also has served as Vice Chair for Research in the Department of Pediatrics at the Floating Hospital for Children at Tufts Medical Center.

Chlamydia research is the systematic study of the organisms in the taxonomic group of bacteria Chlamydiota, the diagnostic procedures to treat infections, the disease chlamydia, infections caused by the organisms, the epidemiology of infection and the development of vaccines. The process of research can include the participation of many researchers who work in collaboration from separate organizations, governmental entities and universities.

<span class="mw-page-title-main">Euan Ashley</span> American professor of medicine

Euan Angus Ashley is a Scottish physician, scientist, author, and founder based at Stanford University in California where he is Associate Dean in the School of Medicine and holds the Roger and Joelle Burnell Chair of Genomics and Precision Health. He is known for helping establish the field of medical genomics.

Elective genetic and genomic testing are DNA tests performed for an individual who does not have an indication for testing. An elective genetic test analyzes selected sites in the human genome while an elective genomic test analyzes the entire human genome. Some elective genetic and genomic tests require a physician to order the test to ensure that individuals understand the risks and benefits of testing as well as the results. Other DNA-based tests, such as a genealogical DNA test do not require a physician's order. Elective testing is generally not paid for by health insurance companies. With the advent of personalized medicine, also called precision medicine, an increasing number of individuals are undertaking elective genetic and genomic testing.

<span class="mw-page-title-main">Tara N. Palmore</span> American physician-scientist and epidemiologist

Tara N. Palmore is an American physician-scientist and epidemiologist specializing in patient safety through prevention of hospital-acquired infections. As of 2021 she was the hospital epidemiologist at George Washington University School of Medicine and Health Sciences.

References

  1. ↑ Captain, Sean (2015-11-03). "Welcome to the Cloud Hospital, Where Big Data Takes On Mysterious Medical Conditions". Fast Company. Retrieved 23 November 2015.
  2. ↑ Gahl, William A.; Wise, Anastasia L.; Ashley, Euan A. (3 November 2015). "The Undiagnosed Diseases Network of the National Institutes of Health". JAMA. 314 (17): 1797–8. doi:10.1001/jama.2015.12249. PMID   26375289.
  3. ↑ Hartnett, Kevin. "A powerful new way to diagnose mystery illnesses". Boston Globe. Retrieved 23 November 2015.
  4. ↑ "Undiagnosed Diseases Network (UDN)". The Common Fund. National Institutes of Health Office of Strategic Coordination. Retrieved 23 November 2015.
  5. ↑ Splinter, Kimberly; Adams, David R.; Bacino, Carlos A.; Bellen, Hugo J.; Bernstein, Jonathan A.; Cheatle-Jarvela, Alys M.; Eng, Christine M.; Esteves, Cecilia; Gahl, William A.; Hamid, Rizwan; Jacob, Howard J.; Kikani, Bijal; Koeller, David M.; Kohane, Isaac S.; Lee, Brendan H.; Loscalzo, Joseph; Luo, Xi; McCray, Alexa T.; Metz, Thomas O.; Mulvihill, John J.; Nelson, Stanley F.; Palmer, Christina G.S.; Phillips, John A.; Pick, Leslie; Postlethwait, John H.; Reuter, Chloe; Shashi, Vandana; Sweetser, David A.; Tifft, Cynthia J.; Walley, Nicole M.; Wangler, Michael F.; Westerfield, Monte; Wheeler, Matthew T.; Wise, Anastasia L.; Worthey, Elizabeth A.; Yamamoto, Shinya; Ashley, Euan A. (29 November 2018). "Effect of Genetic Diagnosis on Patients with Previously Undiagnosed Disease". New England Journal of Medicine. 379 (22): 2131–2139. doi: 10.1056/NEJMoa1714458 . PMC   6481166 .
  6. ↑ Gahl, William A.; Wise, Anastasia L.; Ashley, Euan A. (3 November 2015). "The Undiagnosed Diseases Network of the National Institutes of Health: A National Extension". JAMA. 314 (17): 1797. doi:10.1001/jama.2015.12249.
  7. ↑ Spillmann, Rebecca C.; McConkie-Rosell, Allyn; Pena, Loren; Jiang, Yong-Hui; Schoch, Kelly; Walley, Nicole; Sanders, Camilla; Sullivan, Jennifer; Hooper, Stephen R.; Shashi, Vandana (17 April 2017). "A window into living with an undiagnosed disease: illness narratives from the Undiagnosed Diseases Network". Orphanet Journal of Rare Diseases. 12 (1): 71. doi:10.1186/s13023-017-0623-3. PMC   5392939 . PMID   28416019.
  8. 1 2 3 "UDN Sites". UDN. Retrieved 8 January 2019.
  9. ↑ Gahl, William A. (2011-05-11). "The NIH Undiagnosed Diseases Program". JAMA. 305 (18): 1904–5. doi:10.1001/jama.2011.613. ISSN   0098-7484. PMID   21558523.
  10. ↑ Collins, Francis S.; Varmus, Harold (2015-02-26). "A New Initiative on Precision Medicine". New England Journal of Medicine. 372 (9): 793–795. doi:10.1056/nejmp1500523. ISSN   0028-4793. PMC   5101938 . PMID   25635347.
  11. ↑ Gahl, William A.; Mulvihill, John J.; Toro, Camilo; Markello, Thomas C.; Wise, Anastasia L.; Ramoni, Rachel B.; Adams, David R.; Tifft, Cynthia J. (April 2016). "The NIH Undiagnosed Diseases Program and Network: Applications to modern medicine". Molecular Genetics and Metabolism. 117 (4): 393–400. doi:10.1016/j.ymgme.2016.01.007. ISSN   1096-7192. PMC   5560125 .
  12. ↑ "Undiagnosed Diseases Network". UDN. Retrieved 2019-12-03.
  13. 1 2 3 4 "UDN Manual of Operations". UDN. Retrieved 2019-12-03.
  14. ↑ "Model Organisms". UDN. Retrieved 2019-12-03.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.